Upadacitinib Leads in Efficacy: A Bayesian Network Meta-Analysis of Four JAK Inhibitors in Moderate-To-Severe Atopic Dermatitis.

BACKGROUND: Janus kinase inhibitors (JAKis) have revolutionized the management of moderate-to-severe atopic dermatitis (AD). Although agents approved by the United States Food and Drug Administration (FDA), such as upadacitinib and abrocitinib, are w…

Preview only. Read the full abstract at the source